Gilead Sciences is experiencing significant downward pressure today following the release of its latest quarterly financial results and a subsequent downward revision of its full-year earnings guidance. The primary driver behind the negative sentiment is a reported deceleration in the company core HIV franchise sales. While Gilead remains a dominant player in this space, the pace of adoption for its newer long-acting regimens has not been sufficient to offset the competitive pricing pressures and patent-related concerns surrounding its legacy products. This revenue miss in the most critical segment of its business has led to a reassessment of the company near-term growth profile.

Further weighing on the stock are concerns regarding the…